BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1017 related articles for article (PubMed ID: 23043193)

  • 1. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.
    Solomon TP; Knudsen SH; Karstoft K; Winding K; Holst JJ; Pedersen BK
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4682-91. PubMed ID: 23043193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction.
    Stumvoll M; Fritsche A; Stefan N; Hardt E; Häring H
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1235-9. PubMed ID: 11238514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
    Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Kjems LL; Holst JJ; Vølund A; Madsbad S
    Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.
    Kruszynska YT; Goulas S; Wollen N; McIntyre N
    J Hepatol; 1998 Feb; 28(2):280-91. PubMed ID: 9514541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients With Long-QT Syndrome Caused by Impaired
    Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
    Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.
    Fritsche A; Stefan N; Hardt E; Schützenauer S; Häring H; Stumvoll M
    Eur J Clin Invest; 2000 May; 30(5):411-8. PubMed ID: 10809901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acute exercise on pancreatic endocrine function in subjects with type 2 diabetes.
    Knudsen SH; Karstoft K; Winding K; Holst JJ; Pedersen BK; Solomon TP
    Diabetes Obes Metab; 2015 Feb; 17(2):207-10. PubMed ID: 25406646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
    Ahrén B; Larsson H; Holst JJ
    J Clin Endocrinol Metab; 1997 Feb; 82(2):473-8. PubMed ID: 9024239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
    Salehi M; Vahl TP; D'Alessio DA
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4909-16. PubMed ID: 18827000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects. Assessments using hyperglycemic glucose clamps and oral glucose tolerance tests.
    van Haeften TW; Dubbeldam S; Zonderland ML; Erkelens DW
    Diabetes Care; 1998 Feb; 21(2):278-82. PubMed ID: 9539996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired incretin secretion and pancreatic dysfunction with older age and diabetes.
    Geloneze B; de Oliveira Mda S; Vasques AC; Novaes FS; Pareja JC; Tambascia MA
    Metabolism; 2014 Jul; 63(7):922-9. PubMed ID: 24854384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.